COVID-19 Fast Response Service
The EU-AMRI Covid-19 Fast Response Service is a coordinated and accelerated procedure for researchers to access the academic facilities, services and resources of the EU-AMRI medical research infrastructures:
Biomaterials and associated clinical data
2019-nCoV challenge studies in NHPs under BSL3+
Advanced preclinical models including NHPs, with advanced analytical readouts including molecular and structural imaging (including real time imaging of lung lesions), available under BSL 3 conditions
Immunomonitoring and virological assays
High throughput screening supporting diagnostics, genotyping, phenotyping and drug repurposing
Clinical isolation units
Expertise in pharmacology and protein-drug interaction modeling
Regulatory support, including:
Scientific advice procedure with the European Medicines Agency or national authorities
Advice on ethical, regulatory and legal issues in EU member states for clinical trials; Ethics approval submissions; initiation and monitoring of recruiting sites
Multinational clinical trial support
Certified Data Centers for the management of clinical trial data
Access to large EU-funded platform trials in intensive care, hospitalised or primary care patients
Life Science Research Infrastructures respond to Covid-19
To support the global effort to tackle the coronavirus pandemic, Life Sciences Research Infrastructures (LS RIs) are prioritising COVID-19 research, as detailed on the special LifeScience-RI website here.
The benefits of using established Research Infrastructures are clear: they are ready and able to provide expert advice and resources to meet a variety of research needs.
This video presents how 9 of the European Life Science Research Infrastructures can be used to advance research on coronavirus and other diseases.
Learn more about the Life Science Research Infrastructures